Gilead Faces Setback as Key Lung Cancer Drug Trial Falls Short, Shares Plummet Over 10%
Shares of biopharmaceutical company Gilead Sciences experienced a sharp decline of more than 10% on Monday following disappointing results from a late-stage trial of its